Use of this site and material contained on its pages is for EDUCATIONAL USE ONLY.
 
Ceptic Online - View Patient Profiles

Patel, Dahlia
MRN: 298415 Room: Exam #2 DOB: 6/12/1962 Age: 63 Gender: Female Allergies: Cephalexin (rash)
 Admit Notes
 Clinical Notes
 Vitals
 Labs, Cultures, Imaging
 Clinical Calculators
 MAR
 Current Orders
 Home Med List
 Med Reconciliation
 Discharge Planning
Setting Cancer Center Clinic
Scenario The attending physician will admit the patient to the inpatient hospital ward for treatment. As the clinical pharmacist, you are seeing the patient for the first time with the attending physician at this time. The attending has stated that she is not considering adding any new therapy for DP’s cancer treatment, but would entertain any recommendations you may have on her current regimen. The attending considerers DP’s diarrhea as grade II, which is defined as an increase of 4-6 stools/day over baseline, not interfering with activities of daily living.
Admission note taken on 10/19/25
CC diarrhea, SOB, rash (face and back)
HPI DP presents to the medical oncology clinic today for diarrhea which she describes as 4-6 more stools over baseline, but it does not interfere with her activities of daily living. She also states she has a rash on her face and back. She also complains of progressively worsening shortness of breath. Finally the patient reports increased left arm pain of 7/10 intensity, changed from a baseline 2/10 intensity 3 months ago.
PMH
  • Metastatic breast cancer (ER /PR negative, Her2Neu positive) treated with left mastectomy, trastuzumab, and FAC (5-flurorouracil, doxorubicin, and cyclophosphamide) as adjuvant chemotherapy. DP is also taking a nutritional supplement called Avemar because she heard it could be useful in the treatment of breast cancer. Avemar has been associated with diarrhea, nausea, flatulence, soft stool, and constipation.
  • She developed metastatic disease (to the liver and bones) 6 months ago and is currently on lapatinib and paclitaxel. She has had some worsening dyspnea since starting that regimen.
  • DP also has a 6 month history of neuropathic pain in the left axillary area associated with her malignancy.
  • The patient has no cardiac history and all cardiac studies prior to her cancer therapy have been within normal limits. She has a history of type II diabetes for the past 15 years. She checks her blood glucose before meals and it is usually between 80-100 mg/dL.
  • Two days ago the patient visited her primary care physician for shortness of breath. The physician prescribed clarithromycin for suspected community acquired pneumonia.
Social
History
  • Tobacco: 1 ppd x 35 years, has not smoked in 2 years
  • ETOH: 1-2 drinks/month
  • Illicit Drugs – None
  • Caffeine: 1-2 cups of coffee/day
  • Occupation: Investment banker
  • Status: Married
  • Children: 2 (1 male 40, 1 female 37)
  • Physical Activity: No regular exercise, limited ADLs
  • Diet: No specifics
Family
History
  • Father: 85, alive, DM, HTN
  • Mother: 84, alive, osteoporosis
  • Sister: 60, alive, pancreatic cancer
  • Brother: 66, alive, HTN
Vaccine
History
  • None
Surgical
History
  • None
Physical Exam
  • General: Pleasant, slightly obese woman with slight shortness of breath
  • Skin: Warm, left mastectomy scar present; acneiform rash on face and back
  • Neck/LN: Neck supple; no lymphadenopathy, thyromegaly, or masses. No supraclavicular or infraclavicular adenopathy
  • HEENT: PERRLA, EOMI, pink conjunctivae, TMs intact Chest: crackles at both bases
  • CV: RRR, S1, S1 normal; (+) S3; (–) S4; normal carotid pulses without bruits
  • Abdomen: Soft, obese; hyperactive bowel sounds with diarrhea; no rebound tenderness or guarding; no hepatosplenomegaly
  • Genit/Rect: Deferred
  • MS/Ext: 1+ edema in both lower extremities; no clubbing or cyanosis
  • Neuro: A&O x 3; CN II-XII intact; DTRs 2+ throughout; (–) Babinski, Severe allodynia centered in L axillary region extending from the left mid-clavicular line to the left mid-scapular line between the 2nd and 5th ICS
Clinical Laboratory Report
 
Test Name 10/19/2507/31/25 Range
Sodium (Na+) 138140 136-145 mEq/L
Potassium (K+) 3.74.1 3.5-5 mEq/L
Chloride (Cl-) 104100 98-106 mEq/L
Bicarbonate (HCO3-) 1822 23-28 mEq/L
Urea nitrogen (BUN) 5219 8-20 mg/dL
Creatinine 1.60.8 0.5-1.3 mg/dL
Glucose 10894 70-115 mg/dL
Hemoglobin A1c 7.87.5 5.3-7.5 %
Calcium,Total 10.510.2 8.6-10.2 mg/dL
Phosphate 3.53.6 3-4.5 mg/dL
Magnesium 2.01.9 1.6-2.6 mEq/L
Protein, total 7.17.4 5.5-9 g/dL
Albumin 3.94 3.5-5.5 g/dL
Aminotransferase,aspartate (AST) 115104 10-40 units/L
Aminotransferase,alanine (ALT) 9788 10-40 units/L
Lactic dehydrogenase (LDH) 155162 80-225 units/L
Alkaline phosphatase 7369 30-120 units/L
Bilirubin, Total 0.70.6 0.3-1 mg/dL
Leukocytes (WBC) 9.95.8 4.5-11 x103/mcL
Red blood cells (RBC), Female5.14.94.3-5.7 x108/mcL
Hemoglobin, Female12.513.012-16 g/dL
Hematocrit, Female333637-47 %
Mean corpuscular hemoglobin (MCH) 2931 27-33 picogram
Mean corpuscular volume (MCV) 8681 76-100 mcm3
Platelets 211242 150-450 x103/mcL
International normalized ratio (INR) 1.11.0 0.8-1.2
Prothrombin time (PT) 10.610.2 9.5-11.3 sec
Partial thromboplastin time,activated (aPTT) 3334 25-35 sec

 
 
Additional Labs: Other (today)
  • B-type natriuretic peptide (pg/mL) Pending
Cultures:
  • Stool for ova and parasites (today): negative
  • Clostridium difficile toxin (today): negative
Imaging Studies: Chest X-ray (today)
  • Radiologist preliminary report: Bilateral fluid in bases of lungs, inconsistent with pneumonia.
Multigated acquisition (MUGA) scan (today)
  • Cardiologist preliminary report: EF of 35% (7 months ago previous MUGA reported 55%)
Vital Sign 10/19/25
09:12
07/31/25
07:27
Height (cm) 168168
Weight (kg) 79.573.9
Body Temperature (°C) 37.936.7
Blood Pressure (mmHg) 110 / 75128/90
Heart Rate (bpm) 11067
Respiratory Rate (bpm) 2012
Oxygen Saturation (%) 9297
Current Orders
 
Medication
History
  • The patient reports that she takes all her medications regularly.
  • The patient has not missed any doses of paclitaxel in the clinic and has had consistent refills of lapatinib.
  • All pain medications have been filled regularly, except the controlled release oxycodone has not been filled in the last 2 weeks.
  • She continues to take the oxycodone CR, although she does not take the oxycodone IR since it does not seem to help the pain much. She is not currently comfortable on her current pain regimen.
  • Prior to this clinic visit she was having bowel movements regularly every other day.
  • The herbal product (Avemar) compliance cannot be confirmed, since the patient’s pharmacy does not stock this product. There is no compliance history for the over the counter medication(s).

 
Home Medication List: verified by pharmacy on admit (10/19/25)
 
Patient Name: Patel, Dahlia
Date of Birth: 6/12/1962
Room#: Exam #2
Allergies:
Immunization History:
Community Rx Info:
 
Rx Insurance:
Social History:
Additional Notes:
DRUG
STRENGTH
DF
STRENGTH
ROUTE
FREQ
PRN?
LAST
DOSE
(date/time)
ADVERSE
EFFECTS
ADHERENCE
NOTES
MED REC
ACTION
MED REC
REASON
Action Key:
C = Continue, D = Discontinue*, H = Hold*, M = Modify*
*must provide reason

                    
Medication 10/19/25
Clinical Notes
 
                    
Medication Discharge Orders
 
Hospital Medications
Medication Instructions Comments Continue Modify Discontinue New Rx sent

 
Previous Home Medications
Medication Instructions Comments Continue Modify Discontinue New Rx sent

 
 
Discharge Planning - Medication List and Instructions
 
Patient Name:
Admission Date: Discharge Date: Service:
Principle Diagnosis on Admission:
Secondary Diagnosis:
Allergies:

 
Medications ADDED this visit:
(begin taking these)
Medications CHANGED this visit:
(modify what you were taking)
Medications STOPPED this visit:
(stop taking these)

 
Final Discharge Medication List
Medication/Route/Dosage/Frequency/Duration Comments Morning Afternoon Evening Bedtime
As Needed Medications

 
          
Medication Reconciliation - Finalized Medication List
 
Patient Name: Patel, Dahlia Date of Birth: 6/12/1962 Room: Exam #2

 
Medication (name/strength) Dose Route Frequency Notes